What do systematic reviews say?

Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months) vs placebo

Prednisone (oral, commencing 25 mg with phased dose reduction over 2… led to lower time to resolution of first ulcer (days) compared with placebo; GRADE not reported.

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes

  2 months
  MD -6.35 [-6.74, -5.96]
  1 study · 40 participants
  GRADE not reported

Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months) vs Montelukast (leukotriene receptor antagonist)

Prednisone (oral, commencing 25 mg with phased dose reduction over 2… led to lower time to resolution of first ulcer (days) compared with montelukast (leukotriene receptor antagonist); GRADE not reported.

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes

  2 months
  MD -2.40 [-2.76, -2.04]
  1 study · 40 participants
  GRADE not reported

Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months) vs placebo

Prednisone (oral, commencing 25 mg with phased dose reduction over 2… led to lower total number of new lesions over 2-month treatment period compared with placebo; GRADE not reported.

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes

  2 months
  MD -4.20 [-4.84, -3.56]
  1 study · 40 participants
  GRADE not reported

Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months) vs placebo

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes

  2 months
  Femiano 2003 (high risk of bias) reports days to resolution of pain and days to epithelialization of aphthae at 1 month, and number of aphthae per month after the first and second months; data presented as…
  1 study · 20 participants
  GRADE not reported

Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months) vs placebo

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes

  2 months
  Femiano 2003: one significant adverse event (gastritis) for the prednisone group versus none for placebo. Femiano 2010: more drug-related adverse effects for those treated with prednisone than placebo.
  2 studies
  GRADE not reported

Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months) vs Montelukast (leukotriene receptor antagonist)

Prednisone (oral, commencing 25 mg with phased dose reduction over 2… showed no clear difference in total number of new lesions over 2-month treatment period compared with montelukast (leukotriene receptor antagonist); GRADE not reported.

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes

  2 months
  MD -0.30 [-0.90, 0.30]
  1 study · 40 participants
  GRADE not reported

Prednisone (oral, commencing 25 mg with phased dose reduction over 2 months) vs Montelukast (leukotriene receptor antagonist)

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes

  2 months
  The study reported more drug-related adverse effects for those treated with prednisone than montelukast.
  1 study · 40 participants
  GRADE not reported

DFP and DFO vs DFP

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 369 participants
  Low

DFP and DFO vs DFP

Summary of findings: Comparison 5 ‐ deferiprone (DFP) plus… showed no clear difference in incidence of SAEs compared with DFP (low certainty).

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  RR 0.15 [0.01, 2.81]
  1 study · 213 participants
  Low

DFP and DFO vs DFP

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  0.77 [0.17, 3.42]
  2 studies · 237 participants
  Very low

DFP and DFO vs DFP

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

DFP and DFO vs DFP

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

DFP and DFO vs deferoxamine

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 281 participants
  Low

DFP and DFO vs deferoxamine

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 180 participants
  Low

DFP and DFO vs deferoxamine

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

DFP and DFO vs deferoxamine

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

DFP and DFO vs deferoxamine

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

DFP and DFO vs DFP and DFX

Summary of findings: Comparison 7 ‐ deferiprone (DFP) plus… may leads to lower adherence to iron chelation therapy rates (n, N) compared with DFP plus deferasirox (DFX) (low certainty).

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  RR 0.84 [0.72, 0.99]
  1 study · 96 participants
  Low

DFP and DFO vs DFP and DFX

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  1 [0.06, 16.22]
  1 study · 96 participants
  Very low

DFP and DFO vs DFP and DFX

It is very uncertain whether summary of findings: Comparison 7 ‐ deferiprone (DFP) plus… changes all‐cause mortality ‐ at 1 year ‐ trial end compared with DFP plus deferasirox (DFX) (very low certainty).

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  RD 0
  1 study · 96 participants
  Very low